Peptide Initiative

Peptides · Peptide comparison

Melanotan-2 vs PT-141 (Bremelanotide)

A synthetic copy of the hormone that switches on tanning. Small human trials found it darkened skin without sun exposure and triggered erections in men with erectile dysfunction. It has never been approved by any regulator.

The first FDA-approved peptide that works through your brain to reignite sexual desire—think of it as flipping the 'on' switch for arousal rather than just boosting blood flow like traditional ED meds.

  • Cosmetic
  • Sexual Health

At a glance

Quick comparison

Dose rangeMelanotan-20.5–0.5 mgPT-141 (Bremelanotide)1.75–1.75 mg
FrequencyMelanotan-2Once dailyPT-141 (Bremelanotide)As needed
AdministrationMelanotan-2Subcutaneous injectionPT-141 (Bremelanotide)Subcutaneous injection
Cycle lengthMelanotan-24-6 weeksPT-141 (Bremelanotide)Ongoing/indefinite
Onset speedMelanotan-2Moderate (1-2 weeks)PT-141 (Bremelanotide)Rapid (hours to days)
Evidence levelMelanotan-2Limited human trialsPT-141 (Bremelanotide)Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Tanning Efficacy

Melanotan-295%
PT-141 (Bremelanotide)No recorded rating

Sexual Function

Melanotan-288%
PT-141 (Bremelanotide)No recorded rating

Tan Longevity

Melanotan-285%
PT-141 (Bremelanotide)No recorded rating

Sexual Desire

Melanotan-2No recorded rating
PT-141 (Bremelanotide)92%

On-Demand Use

Melanotan-2No recorded rating
PT-141 (Bremelanotide)95%

Clinical Evidence

Melanotan-2No recorded rating
PT-141 (Bremelanotide)98%

Technical data

Compound specifications

Melanotan-2

Molecular formula
C50H69N15O9
Molecular weight
1024.18 g/mol
Half-life
No human value published. In mice, plasma clearance after injection was rapid; no human pharmacokinetic study located.
Bioavailability
Completely absorbed by subcutaneous injection in humans for the related peptide melanotan-I; not separately measured for melanotan-II in humans
CAS number
121062-08-6

PT-141 (Bremelanotide)

Molecular formula
C50H68N14O10
Molecular weight
1025.2 g/mol
Half-life
2.7 hours
Bioavailability
~100% (subcutaneous injection)
CAS number
189691-06-3

Protocols

Dosing compared

Melanotan-2

Subcutaneous

  • 0.25 mg (250 mcg)Once daily · First 3-5 days (loading)Community-reported starting dose, not peer-reviewed. No clinical trial used a flat 0.25 mg dose. The published human trials dosed by body weight at 0.01-0.03 mg/kg subcutaneously in 3 healthy men [1]. Mild nausea was reported at most dose levels in that trial, which is what starting low is commonly described as managing [1].
  • 0.5 mg (500 mcg)Once daily · Continue loading 7-14 days until desired pigmentationCommunity-reported loading dose, not peer-reviewed. The dose used in every published human trial was 0.025 mg/kg subcutaneously, about 1.75 mg for a 70 kg adult, given to 3 healthy men [1] and to 20 men with erectile dysfunction [4][6][7]. Subcutaneous is the only route with human trial evidence [1]. In the phase-I trial, 0.03 mg/kg produced grade II drowsiness and fatigue in 1 of 2 men who reached that dose, which is why 0.025 mg/kg was the dose carried forward [1].
  • 0.5 mg (500 mcg)2-3 times per week · Ongoing maintenanceCommunity-reported maintenance schedule, not peer-reviewed. No published trial tested a maintenance phase; the longest published human dosing was 10 subcutaneous doses over 2 weeks in 3 healthy men [1]. A systemic-toxicity case followed a 6 mg self-injection, roughly three times the 0.025 mg/kg dose used in trials [9].

PT-141 (Bremelanotide)

Subcutaneous

  • 1 mgAs needed, ~45 min before sexual activity; no more than once per 24 h · Trial period (assess response/tolerability)Not a labelled dose: VYLEESI comes only as a 1.75 mg single-dose autoinjector [7]. A 1 mg starting dose is community practice with compounded powder, used to gauge nausea. Inject into abdomen or thigh.
  • 1.75 mgAs needed, ~45 min before sexual activity; max once per 24 h and 8 doses per 28 days · Ongoing as neededFDA-approved Vyleesi dose for hypoactive sexual desire disorder in premenopausal women; efficacy shown in the RECONNECT phase 3 trials [1][6].

Applications

Best suited for

Melanotan-2

Fair-Skinned Individuals Who Struggle to Tan
If you're the type who burns before you bronze, MT-2 can be a game-changer. It works by telling your skin cells to produce more melanin—the pigment that creates a tan. [13][17] People who normally can't tan often see the most dramatic results.
Those Wanting to Reduce Sun Exposure
MT-2 means you need far less UV exposure to develop and maintain a tan. A few minutes of sun or a brief tanning bed session goes much further. This could potentially reduce your cumulative UV damage over time.
Year-Round Tan Maintenance
Unlike a natural tan that fades quickly, MT-2 tans last longer and can be maintained year-round with minimal upkeep. Many users find they can keep their summer color through winter with just weekly maintenance doses.
Those Experiencing Low Libido
MT-2 has significant effects on sexual arousal and function in both men and women. [18][13] While PT-141 is more targeted for this purpose, [10] some users appreciate getting tanning and libido benefits from one peptide.

PT-141 (Bremelanotide)

Women with Low Sexual Desire (HSDD)
PT-141 is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder—when you used to have normal desire but it's faded, and it's causing real distress in your life. It's the only approved treatment that works through brain pathways rather than hormones.
Men Who Don't Respond to Viagra-Type Medications
While not FDA-approved for men, clinical research shows PT-141 may help men with erectile dysfunction who don't respond to PDE5 inhibitors like Viagra or Cialis. Because it works through the brain rather than blood vessels, it offers a completely different approach.
Those Wanting On-Demand Treatment
Unlike daily medications like flibanserin (Addyi), PT-141 is used only when you want it—take it 45 minutes before intimacy. This gives you control over timing without committing to daily pills.
People Seeking to Address the 'Wanting' Part of Intimacy
Many sexual health treatments focus on the physical mechanics (blood flow, lubrication). PT-141 is unique because it targets desire itself—the psychological 'wanting' that initiates intimacy. It works on your brain's arousal circuits.

Safety profile

Side effects

Melanotan-2

Common

  • Facial flushing
  • Nausea
  • Darkening of moles and freckles
  • Spontaneous erections (men)
  • Drowsiness and fatigue

Uncommon

  • New mole formation
  • Headaches

Serious

  • Priapism (prolonged erection)
  • Concerning mole changes

PT-141 (Bremelanotide)

Common

  • Nausea
  • Facial flushing
  • Headache
  • Injection site reactions

Uncommon

  • Skin darkening (hyperpigmentation)

Serious

  • Blood pressure increase

Research status

Safety & evidence

Melanotan-2

Evidence level
Limited human trials
FDA status
Not FDA approved
Safety overview
Human safety data for melanotan-2 comes from small trials totalling about 23 men, plus a handful of published case reports. In the phase-I study of 3 healthy men, mild nausea was reported at most dose levels, and the 0.03 mg/kg dose caused grade II drowsiness and fatigue in 1 of the 2 men who reached it — which is why 0.025 mg/kg was the dose carried forward [1]. Across 20 men with erectile dysfunction given 0.025 mg/kg, severe nausea occurred in about 1 in 8 (12.9%) [4]. In the psychogenic erectile-dysfunction trial, nausea, stretching and yawning, and reduced appetite were each more common on melanotan-2 than on placebo, though none required treatment [6]. Beyond the trials, single case reports describe rhabdomyolysis (muscle breakdown that can injure the kidneys) after a 6 mg injection [9], ischaemic priapism needing surgery [10], melanoma in a 20-year-old woman who used it alongside sunbeds [8], and mucosal melanoma in a 22-year-old woman who used a nasal spray version [11]. A case report shows that something happened in one person; it cannot show how often it happens.

Contraindications

  • History of melanoma or skin cancer
  • Family history of melanoma
  • Large number of atypical moles
  • Pregnancy or breastfeeding
  • Severe cardiovascular disease

PT-141 (Bremelanotide)

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
PT-141 (bremelanotide) was approved by the FDA in 2019 as VYLEESI after two 24-week phase 3 trials in 1,247 premenopausal women. [1][7] Nausea was the most common reaction (40% vs 1% on placebo): it affected 21% after the first dose and about 3% after later doses, and 8% stopped treatment because of it. [7] Each dose raises blood pressure by up to 6/3 mmHg, peaking 2–4 hours after the dose, and lowers heart rate by up to 5 beats per minute, usually back to baseline within 12 hours. It is contraindicated in uncontrolled hypertension or known cardiovascular disease. [7] Focal hyperpigmentation occurred in 1% at up to 8 doses a month. [7] The 52-week open-label extension found no new safety signals. [2]

Contraindications

  • Uncontrolled high blood pressure [7]
  • Cardiovascular disease [7]
  • History of heart attack or stroke [7]

Decision guide

Which is right for you?

Melanotan-2

Choose Melanotan-2 if…

  • Achieving a natural-looking tan
  • Reducing sun exposure time
  • Enhancing libido and sexual function
  • Appetite suppression

PT-141 (Bremelanotide)

Choose PT-141 (Bremelanotide) if…

  • Restoring sexual desire
  • Treating hypoactive sexual desire disorder (HSDD)
  • Enhancing arousal response
  • Supporting intimacy when desire is low